469 related articles for article (PubMed ID: 29898269)
1. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
2. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Ur Rehman SS; Lim K; Wang-Gillam A
Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis.
Petrelli F; Parisi A; Tomasello G; Mini E; Arru M; Russo A; Garrone O; Khakoo S; Ardito R; Ghidini M
BMC Gastroenterol; 2023 Jun; 23(1):212. PubMed ID: 37337148
[TBL] [Abstract][Full Text] [Related]
4. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.
Usón Junior PLS; Rother ET; Maluf FC; Bugano DDG
Clin Colorectal Cancer; 2018 Sep; 17(3):187-197. PubMed ID: 29615310
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRINOX
Begg SKS; Birnbaum DJ; Clark JW; Mino-Kenudson M; Wellner UF; Schilling O; Lillemoe KD; Warshaw AL; Castillo CF; Liss AS
Anticancer Res; 2020 Jul; 40(7):3659-3667. PubMed ID: 32620605
[TBL] [Abstract][Full Text] [Related]
8. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
Cinar P; Ko AH
Chin Clin Oncol; 2017 Jun; 6(3):29. PubMed ID: 28705006
[TBL] [Abstract][Full Text] [Related]
9. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
10. Selecting chemotherapy for pancreatic cancer: Far away or so close?
Shi S; Yu X
Semin Oncol; 2019 Feb; 46(1):39-47. PubMed ID: 30611527
[TBL] [Abstract][Full Text] [Related]
11. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
12. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
[TBL] [Abstract][Full Text] [Related]
13. New Advances in the Treatment of Metastatic Pancreatic Cancer.
Schober M; Javed MA; Beyer G; Le N; Vinci A; Sund M; Neesse A; Krug S
Digestion; 2015; 92(3):175-84. PubMed ID: 26372949
[TBL] [Abstract][Full Text] [Related]
14. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy.
Erstad DJ; Sojoodi M; Taylor MS; Ghoshal S; Razavi AA; Graham-O'Regan KA; Bardeesy N; Ferrone CR; Lanuti M; Caravan P; Tanabe KK; Fuchs BC
Dis Model Mech; 2018 Jul; 11(7):. PubMed ID: 29903803
[TBL] [Abstract][Full Text] [Related]
15. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Schwarz L; Vernerey D; Bachet JB; Tuech JJ; Portales F; Michel P; Cunha AS
BMC Cancer; 2018 Jul; 18(1):762. PubMed ID: 30041614
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
17. Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma.
Sarfraz H; Saha A; Jhaveri K; Kim DW
Curr Oncol; 2023 May; 30(6):5322-5336. PubMed ID: 37366887
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
Rubinson DA; Wolpin BM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
[TBL] [Abstract][Full Text] [Related]
19. Response in
Campoverde LE; Batalini F; Bulushi Y; Bullock A
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35487638
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic ductal adenocarcinoma: metastatic disease.
Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]